Analysis of the clinical effect of sevelamer carbonate tablets in the treatment of hyperphosphatemia in maintenance hemodialysis patients
Objective To analyze the clinical effect of sevelamer carbonate tablets in the treatment of hyperphosphatemia in maintenance hemodialysis (MHD) patients. Methods 225 MHD patients with hyperphosphatemia were divided into Group A (n=75,treated with sevelamer carbonate tablets),Group B (n=75,treated with lanthanum carbonate chewable tablets) and Group C[n=75,treated with calcium carbonate D3 chewable tablets (Ⅱ)]according to random number method. Comparison was made on efficacy,and the blood calcium,blood phosphorus,calcium-phosphorus product,the level of intact parathyroid hormone (iPTH) before and after treatment,and the occurrence of adverse reactions among the three groups. Results After treatment,the effective rate of Group A was 86.67％,Group B was 69.33％ and Froup C was 21.33％. The effective rate of Group A and Group B was higher than that of Group C,and the effective rate of Group A was higher than that of Group B. The difference was statistically significant (P<0.05). In group A,the blood calcium,blood phosphorus,calcium-phosphorus product after 3 and 6 months of treatment were[(1.98±0.30) and (1.97±0.20) mmol/L],[(2.11±0.15) and (1.48±0.13) mmol/L],[(58.36±5.10) and (55.28±3.72) mg/dl];in group B,the blood calcium,blood phosphorus,calcium-phosphorus product after 3 and 6 months of treatment were[(1.99±0.20) and (1.98±0.23) mmol/L],[(2.26±0.18) and (1.80±0.15) mmol/L],[(60.84±5.37) and (59.56±5.31) mg/dl];in group C,the blood calcium,blood phosphorus,calcium and phosphorus product after 3 and 6 months of treatment were[(2.11±0.32) and (2.20±0.25) mmol/L],[(2.45±0.12) and (2.35±0.18) mmol/L],[(64.15±6.61) and (65.41±6.83) mg/dl]. The blood calcium of Group A and Group B after 3 and 6 months of treatment was lower than that of Group C,and the blood calcium of Group C after 3 and 6 months of treatment was higher than that before treatment. The difference was statistically significant (P<0.05). The blood phosphorus and calcium-phosphorus product in Group A and Group B after 3 and 6 months of treatment were lower than those before treatment in this group and those in Group C,and the blood phosphorus and calcium-phosphorus product in Group A was lower than that in Group B. The difference was statistically significant (P<0.05). There was no significant difference in iPTH among the three groups before and after treatment (P>0.05). The incidence of adverse reactions was 0 in Group A,17.33％(13/75) in Group B,and 24.00％(18/75) in Group C. The incidence of adverse reactions in Group A was lower than that in Group B and Group C,and the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between Group B and Group C (P>0.05). Conclusion Sevelamer carbonate tablets can effectively reduce high phosphorus levels in MHD patients with hyperphosphatemia and has a relatively low incidence of adverse reactions.
万方数据
维普
